• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Allarity Therapeutics Inc.

    7/26/24 6:04:13 AM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALLR alert in real time by email
    DEFA14A 1 ea021006101-defa14a_allar.htm DEFA14A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 14A

     

    Proxy Statement Pursuant to Section 14(a) of
    the Securities Exchange Act of 1934

     

    Filed by the Registrant ☒

     

    Filed by a Party other than the Registrant ☐

     

    Check the appropriate box:

     

    ☐   Preliminary Proxy Statement
    ☐   Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
    ☐   Definitive Proxy Statement
    ☒   Definitive Additional Materials
    ☐   Soliciting Material under §240.14a-12

     

     Allarity Therapeutics, Inc.

    (Name of Registrant as Specified In Its Charter)

     

    ______________________________________________________________

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

    Payment of Filing Fee (Check all boxes that apply):

     

    ☒   No fee required
    ☐   Fee paid previously with preliminary materials
    ☐   Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     

     

     

     

     

     

     

    24 School Street, 2nd Floor
    Boston, Massachusetts 02108

     

    SUPPLEMENT TO THE PROXY STATEMENT FOR

    THE 2024 ANNUAL MEETING OF STOCKHOLDERS

     

    The following information supplements and amends the definitive proxy statement on Schedule 14A (the “Proxy Statement”) of Allarity Therapeutics, Inc., a Delaware corporation (the “Company”), filed with the Securities and Exchange Commission (the “Commission”) on July 1, 2024, and mailed to all holders of record of the Company’s shares of common stock as of the close of business on June 14, 2024 (the “Record Date”), in connection with the solicitation of proxies by the Company’s board of directors (“Board”) for the annual meeting of stockholders (the “Annual Meeting”) originally intended to be held on July 26, 2024.

     

    POSTPONEMENT OF ANNUAL MEETING OF STOCKHOLDERS

      

    On July 25, 2024, the Board, acting in accordance with the authority granted to the Board pursuant to the applicable provisions of the Company’s bylaws, elected to postpone the Annual Meeting to a date to be determined by the Board in accordance with the applicable provisions of the Company’s bylaws after the date of this supplement to the Proxy Statement (this “Supplement”). The Board will determine the date of the postponed Annual Meeting and, if necessary or appropriate, the new record date for the Annual Meeting, and will deliver a notice of the postponed Annual Meeting and, if applicable, an updated Proxy Statement to all stockholders entitled to vote at the postponed Annual Meeting based on the Record Date or a newly established record date for the postponed Annual Meeting, as applicable. Only stockholders of record as of the close of business on the Record Date or the newly established record date, as applicable, will be entitled to notice of and to vote at the postponed Annual Meeting.

     

    Except as described above, this Supplement does not modify, amend, supplement, or otherwise affect the Proxy Statement. This Supplement should be read in conjunction with the Proxy Statement.

     

    ADDITIONAL INFORMATION AND WHERE TO FIND IT

     

    The Proxy Statement was mailed to all stockholders of record as of the close of business on the Record Date that were entitled to receive notice of and vote at the Annual Meeting. In addition, the Proxy Statement is available free of charge at the Commission’s website located at www.sec.gov.

     

    BEFORE MAKING ANY VOTING OR INVESTMENT DECISIONS, STOCKHOLDERS ARE URGED TO READ THE PROXY STATEMENT AND ALL OTHER RELEVANT DOCUMENTS FILED WITH THE COMMISSION, AS SUCH DOCUMENTS AND FILINGS CONTAIN IMPORTANT INFORMATION ABOUT THE ANNUAL MEETING AND THE MATTERS TO BE ACTED UPON AT THE ANNUAL MEETING.

     

     

     

    Get the next $ALLR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALLR

    DatePrice TargetRatingAnalyst
    7/28/2025$9.00Buy
    Ascendiant Capital Markets
    More analyst ratings

    $ALLR
    SEC Filings

    View All

    SEC Form S-3 filed by Allarity Therapeutics Inc.

    S-3 - Allarity Therapeutics, Inc. (0001860657) (Filer)

    2/12/26 4:18:22 PM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Allarity Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Allarity Therapeutics, Inc. (0001860657) (Filer)

    2/4/26 8:00:35 AM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Allarity Therapeutics Inc.

    424B5 - Allarity Therapeutics, Inc. (0001860657) (Filer)

    1/29/26 8:00:18 AM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Graff Jeremy R. was granted 133,333 shares, increasing direct ownership by 54% to 381,644 units (SEC Form 4)

    4 - Allarity Therapeutics, Inc. (0001860657) (Issuer)

    1/16/26 4:13:58 PM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Officer Graff Jeremy R. converted options into 39,494 shares and covered exercise/tax liability with 14,613 shares (SEC Form 4)

    4 - Allarity Therapeutics, Inc. (0001860657) (Issuer)

    10/2/25 4:05:10 PM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Ervin Jeffrey S

    3 - Allarity Therapeutics, Inc. (0001860657) (Issuer)

    7/14/25 11:51:07 AM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Ascendiant Capital Markets initiated coverage on Allarity Therapeutics with a new price target

    Ascendiant Capital Markets initiated coverage of Allarity Therapeutics with a rating of Buy and set a new price target of $9.00

    7/28/25 8:53:33 AM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Allarity Therapeutics announces that its collaborative Phase 2 trial with the United States Veteran's Administration Combining Stenoparib with Temozolomide in Relapsed Small Cell Lung Cancer is Now Open for Enrollment

             This is the first trial combining Allarity's stenoparib with another anti-cancer agent Stenoparib's favorable safety profile supports potential for use in combination regimens Trial is fully funded by the U.S. Department of Veterans Affairs and is open to enrollment at 11 VA sites throughout the US TARPON SPRINGS, Fla., February 3, 2026 – Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor—today announced that enrollment is now open for its new Phase 2 clinical trial evaluating the combination of stenoparib and temo

    2/3/26 8:00:00 AM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Allarity Therapeutics Issues 2025 End of Year CEO Letter to Shareholders

    TARPON SPRINGS, Fla., December 31, 2025 – Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor—today issued the following letter to shareholders from the Company's Chief Executive Officer.Dear Shareholders, As we close out 2025, I write to you with both optimism and gratitude. Your continued support has helped steer Allarity Therapeutics through a period of meaningful transformation and disciplined execution. This December marks two years since I assumed the role of Chief Executive Officer. Since that time, our efforts have bee

    12/31/25 8:00:00 AM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Allarity Therapeutics Provides Third Quarter 2025 Financial Results and Provides Business Updates

         Received FDA Fast Track designation for stenoparib in advanced ovarian cancer Reported landmark median overall survival now exceeding 25 months in ongoing Phase 2 trialAdvanced DRP® platform through new licensing agreement TARPON SPRINGS, Fla., November 14, 2025 – Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor—today reported financial results and provided an update on operational highlights for the third quarter ended September 30, 2025. "The third quarter of 2025 was another milestone period for Allarity as we ac

    11/14/25 9:00:00 AM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLR
    Leadership Updates

    Live Leadership Updates

    View All

    Allarity Therapeutics Announces Appointment of Jeff Ervin as Chief Financial Officer

        TARPON SPRINGS, Fla., July 7, 2025 -- Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—as a personalized cancer treatment using its proprietary, drug-specific Drug Response Predictor (DRP®) patient selection technology, today announced the appointment of Jeff Ervin as the Company's new Chief Financial Officer (CFO). He succeeds Alexander Epshinsky, who will remain engaged with the Company during a transition period. Mr. Ervin brings nearly two decades of executive leadership experience across the healthcare, biotech, and other

    7/7/25 8:00:00 AM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Allarity Therapeutics Announces Changes to Board of Directors

        TARPON SPRINGS, Fla., June 11, 2025 -- Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—as a personalized cancer treatment using its proprietary, drug-specific Drug Response Predictor (DRP®) patient selection technology—today announced that Jesper Høiland has been appointed to join the Company's Board of Directors. He will be replacing Joseph Vazzano, who will resign from the Board effective on June 30, 2025, following his valuable contributions to Allarity's development over the past two years. Mr. Høiland is already well-acqua

    6/11/25 4:05:00 PM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Allarity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Recent Operational Highlights

      Cash balance at $18.5 millionStrengthened leadership team with new members driving stenoparib developmentNASDAQ compliance regained Boston (November 14, 2024)—Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments using its proprietary, drug-specific patient selection technology, today reported financial results for the third quarter ended September 30, 2024, and provided an update on recent operational highlights. "This quarter's progress marks a steady period of advancement for Allarity as we have maintained a strong cash position, achieved record patient duratio

    11/14/24 8:00:00 AM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Allarity Therapeutics Inc.

    SC 13G/A - Allarity Therapeutics, Inc. (0001860657) (Subject)

    11/13/24 9:24:34 PM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Allarity Therapeutics Inc.

    SC 13G - Allarity Therapeutics, Inc. (0001860657) (Subject)

    8/29/24 3:57:47 PM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Allarity Therapeutics Inc. (Amendment)

    SC 13G/A - Allarity Therapeutics, Inc. (0001860657) (Subject)

    2/12/24 9:52:15 AM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLR
    Financials

    Live finance-specific insights

    View All

    Allarity Therapeutics Provides Third Quarter 2025 Financial Results and Provides Business Updates

         Received FDA Fast Track designation for stenoparib in advanced ovarian cancer Reported landmark median overall survival now exceeding 25 months in ongoing Phase 2 trialAdvanced DRP® platform through new licensing agreement TARPON SPRINGS, Fla., November 14, 2025 – Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor—today reported financial results and provided an update on operational highlights for the third quarter ended September 30, 2025. "The third quarter of 2025 was another milestone period for Allarity as we ac

    11/14/25 9:00:00 AM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Allarity Therapeutics Provides Second Quarter 2025 Update, Highlighting Clinical Progress, IP Expansion, and New Partnerships

        - Successfully initiated enrollment in advanced Phase 2 ovarian cancer trial - Expanded global IP protection by securing Australian patent acceptance for the stenoparib DRP® companion diagnostic- Secured new service contract with EU biotech for Allarity Medical Laboratory TARPON SPRINGS, Fla., August 15, 2025 -- Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—today reported financial results and provided an update on operational highlights for the second quarter ended June 30, 2025. "The second quarter of 2025 marked a period

    8/15/25 4:30:00 PM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Allarity Therapeutics Reports First Quarter Financial Results and Highlights, including Clear Clinical Benefits from Phase 2 Trial, NASDAQ Compliance, and Significant Improvement in Cash and Equity Balances

    - Phase 2 Trial of Stenoparib Concluded Early due to Clear Clinical Benefits Achieved - On Track to Regain Compliance with All Nasdaq Listing Requirements - No Variable Priced Securities are Outstanding - Warrant Overhang Near Elimination - Allarity Withdraws its Form S-1 - Establishes Equity of $15 Million - Cash Balance of $14 Million Boston (May 14, 2024)—Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today reported financial results and provided an update on recent operational highlights for the first quarter that ended March 31, 2024. "The s

    5/14/24 4:01:00 PM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care